Press Release

Global Secondary Hyperparathyroidism Treatment (SHPT) Market Size and Share By Industry Demand, Worldwide Research, Prominent Players, Emerging Trends, Investment Opportunities and Revenue Expectation till 2027

The increasing launch of effective drugs is a key factor driving the “U.S. Secondary Hyperparathyroidism Treatment Market Size” says Fortune Business Insights in a report, titled “Secondary Hyperparathyroidism Treatment Market” ,Size, Share & Industry Analysis, By Drug Class (Calcimimetics, Vitamin D Analogues, and Phosphate Binders), By Distribution Channel (Hospital & Retail Pharmacies, Online Channels, and Others) and Region Forecast, 2019-2026.” The secondary hyperparathyroidism treatment (SHPT) market was valued at USD 4.34 Billion in 2018 and is expected to reach USD 7.06 Billion by 2026, exhibiting a CAGR of 9.0%. As per the report the secondary hyperparathyroidism treatment market on the basis of drug class is segmented into calcimimetics, vitamin d analogues, and phosphate binders.

The calcimimetics segment is expected to hold maximum share during the forecast period owing to the numerous generic substitutes of Cinacalcet in the U.S. along with the rising demand for potent and specific therapy for the treatment of SHPT. For instance, according to a national survey conducted by American Journal of Kidney Diseases the use of Cinacalcet has increased from 23% to 31% between 2014 and 2017

The report provides a comprehensive assessment of the secondary hyperparathyroidism treatment market by inculcating valuable insights, facts, industry-related information, and historical data. Numerous approaches and methods are implemented to make meaningful assumptions and views. Furthermore, it offers a detailed analysis and information as per market segments, helping readers to get an inclusive overview of the market.

Get Request a Sample Copy of the Secondary Hyperparathyroidism Treatment (SHPT) Report:

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-secondary-hyperparathyroidism-shpt-treatment-market-101664

Major Secondary Hyperparathyroidism Treatment (SHPT) Market Key players covered in the report include:

  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Genzyme Corporation (Sanofi)
  • AbbVie Inc.
  • Cipla Inc.
  • Reddy’s Laboratories Ltd.
  • OPKO Health, Inc.
  • Other Prominent Players

Secondary Hyperparathyroidism Treatment (SHPT) Market Analysis 2021:

Emerging Guidelines By Government Authorities Will Boost Growth

The increasing government initiatives for improvising secondary hyperparathyroidism management will create growth opportunities for the secondary hyperparathyroidism treatment market. The aim of SHPT treatment is to manage the biochemical markers of bone and mineral metabolism, which are directly linked to cardiovascular events and bone fractures by extensive epidemiologic evidence. International & national organizations in the U.S. and working groups such as the National Kidney Foundation have published various clinical guidance documents to encourage best practices in managing SHPT. Furthermore, increasing awareness about SHPT in physicians, as well as clinical specialists, have improved the treatment regimen for its management. The improvement in earlier identification and assessment of SHPT for mineral metabolism in CKD & ESRD will have a positive impact on secondary hyperparathyroidism treatment market growth. The reduction in associated complications for the management of SHPT is expected to accelerate growth of the market during the forecast period.

Please Visit: https://www.fortunebusinessinsights.com/industry-reports/u-s-secondary-hyperparathyroidism-shpt-treatment-market-101664

Rising Prevalence Of Chronic Kidney Disease Will Stimulate Growth

The increasing prevalence of chronic kidney disease among geriatric population as well as general population will enable the growth of the secondary hyperparathyroidism treatment market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), around 15% of U.S adults, which, is, 37 million people are estimated to have chronic kidney disease. Additionally, CKD is found more common in people aged 65 years or older than in people aged 45-64 years. The rising cases of renal disease and increasing patient pool will have a significant impact on the market.  The increasing cost burden for the treatment of secondary hyperparathyroidism will further encourage growth of the market. In addition, the launch of generic form of Cinacalcet hydrochloride tablets will bode well for the secondary hyperparathyroidism treatment market. For instance, Cipla Inc. and its subsidiary Cipla USA Inc. announced the launch of a generic form of Cinacalcet hydrochloride tablets in USA. Moreover, Amgen Inc. announced the USFDA approval of Parsabiv for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD). The approval for Parsabiv will also aid the growth of the market during the forecast period.

Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/u-s-secondary-hyperparathyroidism-shpt-treatment-market-101664

Table of Content:

1 Secondary Hyperparathyroidism Treatment (SHPT) Market Overview

1.1 Secondary Hyperparathyroidism Treatment (SHPT) Product Overview

1.2 Secondary Hyperparathyroidism Treatment (SHPT) Market Segment by Type

1.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Size by Type (2015-2027)

1.3.1 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Size Overview by Type (2015-2027)

1.3.2 Global Secondary Hyperparathyroidism Treatment (SHPT) Historic Market Size Review by Type (2015-2021)

1.3.2.1 Global Secondary Hyperparathyroidism Treatment (SHPT) Sales Market Share Breakdown by Type (2015-2027)

1.3.2.2 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Share Breakdown by Type (2015-2027)

1.3.2.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Average Selling Price (ASP) by Type (2015-2027)

1.3.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Size Forecast by Type (2021-2027)

1.3.3.1 Global Secondary Hyperparathyroidism Treatment (SHPT) Sales Market Share Breakdown by Application (2021-2027)

1.3.3.2 Global Secondary Hyperparathyroidism Treatment (SHPT) Revenue Market Share Breakdown by Application (2021-2027)

1.3.3.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Average Selling Price (ASP) by Application (2021-2027)

1.4 Key Regions Market Size Segment by Type (2015-2021)

1.4.1 North America Secondary Hyperparathyroidism Treatment (SHPT) Sales Breakdown by Type (2015-2027)

1.4.2 Europe Secondary Hyperparathyroidism Treatment (SHPT) Sales Breakdown by Type (2015-2027)

1.4.3 Asia-Pacific Secondary Hyperparathyroidism Treatment (SHPT) Sales Breakdown by Type (2015-2027)

1.4.4 Latin America Secondary Hyperparathyroidism Treatment (SHPT) Sales Breakdown by Type (2015-2027)

1.4.5 Middle East and Africa Secondary Hyperparathyroidism Treatment (SHPT) Sales Breakdown by Type (2015-2027)

2 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Competition by Company

2.1 Global Top Players by Secondary Hyperparathyroidism Treatment (SHPT) Sales (2015-2021)

2.2 Global Top Players by Secondary Hyperparathyroidism Treatment (SHPT) Revenue (2015-2021)

2.3 Global Top Players Secondary Hyperparathyroidism Treatment (SHPT) Average Selling Price (ASP) (2015-2021)

2.4 Global Top Company Secondary Hyperparathyroidism Treatment (SHPT) Manufacturing Base Distribution, Sales Area, Product Type

2.5 Secondary Hyperparathyroidism Treatment (SHPT) Market Competitive Situation and Trends

2.5.1 Secondary Hyperparathyroidism Treatment (SHPT) Market Growth Rate (2015-2021)

2.5.2 Global 5 and 10 Largest Company by Secondary Hyperparathyroidism Treatment (SHPT) Sales and Revenue in 2019

2.6 Global Top Company by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Secondary Hyperparathyroidism Treatment (SHPT) as of 2019)

2.7 Date of Key Company Enter into Secondary Hyperparathyroidism Treatment (SHPT) Market

2.8 Key Company Secondary Hyperparathyroidism Treatment (SHPT) Product Offered

2.9 Mergers and Acquisitions, Expansion

3 Global Secondary Hyperparathyroidism Treatment (SHPT) Status and Outlook by Region (2015-2027)

3.1 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Size and CAGR by Region: 2015 VS 2021 VS 2027

3.2 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Size Market Share by Region (2015-2021)

3.2.1 Global Secondary Hyperparathyroidism Treatment (SHPT) Sales Market Share by Region (2015-2021)

3.2.2 Global Secondary Hyperparathyroidism Treatment (SHPT) Revenue Market Share by Region (2015-2021)

3.2.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Sales, Revenue, Price and Gross Margin (2015-2021)

3.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Size Market Share by Region (2021-2027)

3.3.1 Global Secondary Hyperparathyroidism Treatment (SHPT) Sales Market Share by Region (2021-2027)

3.3.2 Global Secondary Hyperparathyroidism Treatment (SHPT) Revenue Market Share by Region (2021-2027)

3.3.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Sales, Revenue, Price and Gross Margin (2021-2027)

3.4 North America Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

3.4.1 North America Secondary Hyperparathyroidism Treatment (SHPT) Revenue By Growth (2015-2027)

3.4.2 North America Secondary Hyperparathyroidism Treatment (SHPT) Sales By Growth (2015-2027)

3.5 Asia-Pacific Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

3.5.1 Asia-Pacific Secondary Hyperparathyroidism Treatment (SHPT) Revenue By Growth (2015-2027)

3.5.2 Asia-Pacific Secondary Hyperparathyroidism Treatment (SHPT) Sales By Growth (2015-2027)

3.6 Europe Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

3.6.1 Europe Secondary Hyperparathyroidism Treatment (SHPT) Revenue By Growth (2015-2027)

3.6.2 Europe Secondary Hyperparathyroidism Treatment (SHPT) Sales By Growth (2015-2027)

3.7 Latin America Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

3.7.1 Latin America Secondary Hyperparathyroidism Treatment (SHPT) Revenue By Growth (2015-2027)

3.7.2 Latin America Secondary Hyperparathyroidism Treatment (SHPT) Sales By Growth (2015-2027)

3.8 Middle East and Africa Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

3.8.1 Middle East and Africa Secondary Hyperparathyroidism Treatment (SHPT) Revenue By Growth (2015-2027)

3.8.2 Middle East and Africa Secondary Hyperparathyroidism Treatment (SHPT) Sales By Growth (2015-2027)

4 Global Secondary Hyperparathyroidism Treatment (SHPT) by Application

4.1 Secondary Hyperparathyroidism Treatment (SHPT) Segment by Application

4.1.1 Residential

4.1.2 Commercial

4.2 Global Secondary Hyperparathyroidism Treatment (SHPT) Sales by Application: 2015 VS 2021 VS 2027

4.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Historic Sales by Application (2015-2021)

4.4 Global Secondary Hyperparathyroidism Treatment (SHPT) Forecasted Sales by Application (2021-2027)

4.5 Key Regions Secondary Hyperparathyroidism Treatment (SHPT) Market Size by Application

4.5.1 North America Secondary Hyperparathyroidism Treatment (SHPT) by Application

4.5.2 Europe Secondary Hyperparathyroidism Treatment (SHPT) by Application

4.5.3 Asia-Pacific Secondary Hyperparathyroidism Treatment (SHPT) by Application

4.5.4 Latin America Secondary Hyperparathyroidism Treatment (SHPT) by Application

4.5.5 Middle East and Africa Secondary Hyperparathyroidism Treatment (SHPT) by Application

5 North America Secondary Hyperparathyroidism Treatment (SHPT) Market Size by Country (2015-2027)

5.1 North America Market Size Market Share by Country (2015-2021)

5.1.1 North America Secondary Hyperparathyroidism Treatment (SHPT) Sales Market Share by Country (2015-2021)

5.1.2 North America Secondary Hyperparathyroidism Treatment (SHPT) Revenue Market Share by Country (2015-2021)

5.2 North America Market Size Market Share by Country (2021-2027)

5.2.1 North America Secondary Hyperparathyroidism Treatment (SHPT) Sales Market Share by Country (2021-2027)

5.2.2 North America Secondary Hyperparathyroidism Treatment (SHPT) Revenue Market Share by Country (2021-2027)

5.3 North America Market Size By Growth by Country

5.3.1 U.S. Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

5.3.2 Canada Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

6 Europe Secondary Hyperparathyroidism Treatment (SHPT) Market Size by Country (2015-2027)

6.1 Europe Market Size Market Share by Country (2015-2021)

6.1.1 Europe Secondary Hyperparathyroidism Treatment (SHPT) Sales Market Share by Country (2015-2021)

6.1.2 Europe Secondary Hyperparathyroidism Treatment (SHPT) Revenue Market Share by Country (2015-2021)

6.2 Europe Market Size Market Share by Country (2021-2027)

6.2.1 Europe Secondary Hyperparathyroidism Treatment (SHPT) Sales Market Share by Country (2021-2027)

6.2.2 Europe Secondary Hyperparathyroidism Treatment (SHPT) Revenue Market Share by Country (2021-2027)

6.3 Europe Market Size By Growth by Country

6.3.1 Germany Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

6.3.2 France Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

6.3.3 U.K. Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

6.3.4 Italy Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

6.3.5 Russia Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

7 Asia-Pacific Secondary Hyperparathyroidism Treatment (SHPT) Market Size by Country (2015-2027)

7.1 Asia-Pacific Market Size Market Share by Country (2015-2021)

7.1.1 Asia-Pacific Secondary Hyperparathyroidism Treatment (SHPT) Sales Market Share by Country (2015-2021)

7.1.2 Asia-Pacific Secondary Hyperparathyroidism Treatment (SHPT) Revenue Market Share by Country (2015-2021)

7.2 Asia-Pacific Market Size Market Share by Country (2021-2027)

7.2.1 Asia-Pacific Secondary Hyperparathyroidism Treatment (SHPT) Sales Market Share by Country (2021-2027)

7.2.2 Asia-Pacific Secondary Hyperparathyroidism Treatment (SHPT) Revenue Market Share by Country (2021-2027)

7.3 Asia-Pacific Market Size By Growth by Country

7.3.1 China Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

7.3.2 Japan Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

7.3.3 South Korea Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

7.3.4 India Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

7.3.5 Australia Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

7.3.6 Taiwan Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

7.3.7 Indonesia Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

7.3.8 Thailand Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

7.3.9 Malaysia Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

7.3.10 Philippines Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

Continue…

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune -411045, Maharashtra, India.

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

 

Related Reports :

Germany Hepatitis C Testing Market 

Immunomodulators Market 

Latin America Eyewear Market 

Point-of-care Ultrasound Market 

Portable Ultrasound Market 

Infectious Disease Point of Care Diagnostics Market 

Medical X-ray Market 

Point of Care (POC) CT Imaging Systems Market 

Central Nervous System Treatment Market 

Dental CAD/CAM Market 

Germany Hepatitis C Testing Market Size

Immunomodulators Market Size

Latin America Eyewear Market Size

Point-of-care Ultrasound Market Size

Portable Ultrasound Market Size

Infectious Disease Point of Care Diagnostics Market Size

Medical X-ray Market Size

Point of Care (POC) CT Imaging Systems Market Size

Central Nervous System Treatment Market Size

Dental CAD/CAM Market Size

Tags

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close